The sudden cessation of #PEPFAR funding likely results in tens of thousands of #HIV deaths and new infections
www.thelancet.com/journals/ecl...
#MedSky
The sudden cessation of #PEPFAR funding likely results in tens of thousands of #HIV deaths and new infections
www.thelancet.com/journals/ecl...
#MedSky
Here's a wee thread to explain what we've done 😉
Here's a wee thread to explain what we've done 😉
bit.ly/4lowp18
bit.ly/4lowp18
Last year on our Trial Talk podcast, we interviewed #TB #ClinicalTrials legends Andrew Nunn and Sarah Meredith about their accomplished careers. Tune in 👇
Last year on our Trial Talk podcast, we interviewed #TB #ClinicalTrials legends Andrew Nunn and Sarah Meredith about their accomplished careers. Tune in 👇
#Tuberculosis - or TB - is caused by bacteria Mycobacterium tuberculosis that mainly affects the lungs.
Common symptoms include
❗️ Cough
❗️ Chest pains
❗️ Weight loss
❗️ Fever
❗️ Night sweats
Learn more about TB 👉 bit.ly/3yYNwzx #EndTB
#Tuberculosis - or TB - is caused by bacteria Mycobacterium tuberculosis that mainly affects the lungs.
Common symptoms include
❗️ Cough
❗️ Chest pains
❗️ Weight loss
❗️ Fever
❗️ Night sweats
Learn more about TB 👉 bit.ly/3yYNwzx #EndTB
This paper explores the application of the estimands framework to trials in #IBD #InflammatoryBowelDisease. 👇
This paper explores the application of the estimands framework to trials in #IBD #InflammatoryBowelDisease. 👇
Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis recurrence in HIV-negative adults successfully treated for pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trial
www.thelancet.com/journals/lan...
Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis recurrence in HIV-negative adults successfully treated for pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trial
www.thelancet.com/journals/lan...
In this podcast episode, @brennankahan.bsky.social discusses his work on estimands.
🎧Listen to short clip below & tune in to the episode👉 https://buff.ly/3PtETFq
In this podcast episode, @brennankahan.bsky.social discusses his work on estimands.
🎧Listen to short clip below & tune in to the episode👉 https://buff.ly/3PtETFq
🗓️ Wed. Jan. 8
🕔 16:00 Berlin time (CET)
📍 Zoom webinar
Abstract + webinar sign up link: bemcolloquium.com/meetings-cal...
#EpiSky #CausalSky
🗓️ Wed. Jan. 8
🕔 16:00 Berlin time (CET)
📍 Zoom webinar
Abstract + webinar sign up link: bemcolloquium.com/meetings-cal...
#EpiSky #CausalSky
trialsjournal.biomedcentral.com/articles/10....
trialsjournal.biomedcentral.com/articles/10....
I would interested to hear about the barriers you face in implementing reproducible practices in your research (e.g., version control, code review, reproducible documents).
Be sure to check out this introduction from @vincentab.bsky.social, @noahgreifer.bsky.social. and @andrew.heiss.phd!
#EpiSky
And now I get to focus on {marginaleffects} 1.0.0. Stay tuned.
www.jstatsoft.org/article/view...
Be sure to check out this introduction from @vincentab.bsky.social, @noahgreifer.bsky.social. and @andrew.heiss.phd!
#EpiSky
Implications of a trace Xpert Ultra (Joowhan Sung)
- 129 pts with trace Ultra were thoroughly investigated at baseline + followed up for 2 yrs
- ½ of pts diagnosed w/ prevalent or incident TB
- Incident TB strongly associated w/ abnormal CXR but NOT symptoms - supports symptom-agnostic testing
www.bennett.ox.ac.uk/blog/2024/10...
www.bennett.ox.ac.uk/blog/2024/10...